Valuation: Zai Lab Limited

Market Cap 215.95Cr 190.01Cr 176.58Cr 162.13Cr 304.31Cr 21TCr 309.42Cr 2.1TCr 818.98Cr 10TCr 810.62Cr 793.15Cr 35TCr P/E 2026 *
-8.68x
P/E 2027 * -10.3x
Enterprise Value 171.63Cr 151.02Cr 140.34Cr 128.86Cr 241.87Cr 17TCr 245.93Cr 1.67TCr 650.92Cr 8.12TCr 644.28Cr 630.39Cr 28TCr EV / Sales 2026 *
3.83x
EV / Sales 2027 * 2.98x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 215.95Cr
+0.63%-3.06%+16.18%-9.78% 6.67TCr
+1.23%+2.80%+37.51%+202.14% 5.33TCr
+10.08%+51.80%+51.80%+51.80% 4.81TCr
-1.32%-7.38%-57.63%-57.10% 3.83TCr
+0.78%-1.84%+52.49%-27.01% 2.99TCr
+0.84%+0.36%+66.93%+85.42% 2.35TCr
-5.17%-12.54%+58.98%-56.04% 2.15TCr
-1.21%+1.12%+1.98%+170.93% 2TCr
-0.22%-0.95%+61.97%+123.78% 1.64TCr
Average +0.56%-1.00%+32.25%+53.79% 3.53TCr
Weighted average by Cap. +1.40%-0.11%+27.80%+49.98%

Financials

2026 *2027 *
Net sales 45Cr 39Cr 37Cr 34Cr 63Cr 4.33TCr 64Cr 435.76Cr 170.17Cr 2.12TCr 168.43Cr 164.8Cr 7.35TCr 60Cr 52Cr 49Cr 45Cr 84Cr 5.75TCr 85Cr 578.4Cr 225.87Cr 2.82TCr 223.57Cr 218.75Cr 9.75TCr
Net income -24Cr -21Cr -20Cr -18Cr -34Cr -2.33TCr -35Cr -233.95Cr -91Cr -1.14TCr -90Cr -88Cr -3.95TCr -16Cr -14Cr -13Cr -12Cr -22Cr -1.51TCr -22Cr -151.96Cr -59Cr -740.57Cr -59Cr -57Cr -2.56TCr
Net Debt -44Cr -39Cr -36Cr -33Cr -62Cr -4.28TCr -63Cr -430.35Cr -168.06Cr -2.1TCr -166.34Cr -162.76Cr -7.26TCr -39Cr -34Cr -32Cr -29Cr -55Cr -3.74TCr -55Cr -376.03Cr -146.84Cr -1.83TCr -145.34Cr -142.21Cr -6.34TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A